Immunochromatographic Strip Test Developed for Rift Valley Fever
|
By LabMedica International staff writers Posted on 03 Oct 2019 |

Image: Rift Valley Fever (RVF) lateral flow immunochromatographic (LFT) strip test for the detection of RVF infection using the two selected monoclonal antibodies (Photo courtesy of University of Montpellier).
Rift Valley fever (RVF) is an emerging mosquito-borne disease that affects a wide range of animals and human beings in Africa and the Arabian Peninsula. A rapid and specific test for RVF diagnosis at the site of a suspected outbreak is crucial for the implementation of control measures.
Patients who become ill usually experience fever, generalized weakness, back pain, and dizziness at the onset of the illness. Typically, patients recover within two days to one week after onset of illness. However, a small percentage (8-10%) of people infected with RVFV develops much more severe symptoms. There is a growing concern that RVFV will extend its current range due to the wide variety of mosquito species able to transmit to several mammal hosts.
Scientists at the University of Montpellier (Montpellier, France) and their colleagues developed a first-line lateral flow immunochromatographic strip test (LFT) for the detection of the nucleoprotein (N) of the RVF virus (RVFV). Its diagnostic performance characteristics were evaluated using reference stocks isolates recovered from different hosts and in geographic regions mimicking clinical specimens and from known RVF negative serum samples.
The test strip was constructed on the principles of immunochromatography using colloidal-gold-labeled monoclonal antibodies (Mabs). The team used the two Mabs generated against the N protein of RVFV: the Mab 8E10-4A4 gold conjugate and the Mab 10H3-4E4-3D5. Mab 10H3-4E4-3D5 was immobilized onto a nitrocellulose membrane for the test line zone and rabbit anti-mouse antibodies were immobilized for the control line zone to capture unbound Mab. The test (T) and control (C) lines were checked for the development of color after 10 minutes and again after 30 minutes as it might take longer time for weak positives to form a visual band scored subjectively from negative to strong.
A total of 25 isolated strains mimicking clinical specimens of different geographical origins and 10 clinical samples originating from an ongoing outbreak in 2019 detected RVF positive by a TaqMan RT-PCR technique which is considered as the current reference detection system were also detected positive by the LFT giving a diagnostic sensitivity of 100%. Diagnostic specificity (DSp) was assessed on 160 serum samples known to be negative for RVFV by sero-neutralization test and cELISA but collected in tropical countries where RVF has been circulating to detect possible cross reactions or in other areas where RVF introduction is considered at risk. The test gave a DSp of 98.81% and there was an absence of cross-reactivity with viruses belonging to different genera.
The authors concluded that the specificity and sensitivity of the evaluated test are lower than the ones of molecular-based techniques (LAMP, PCR) but are adequate for specific rapid initial detection of RVF outbreaks or disease surveillance in control programs. The fact no specialized reagents and laboratory equipment are needed, make this assay a valuable, first-line diagnostic tool in resource-poor diagnostic territories for on-site RVFV detection, however the staff require training. The study was published on September 11, 2019, in the journal PLOS NTD.
Related Links:
University of Montpellier
Patients who become ill usually experience fever, generalized weakness, back pain, and dizziness at the onset of the illness. Typically, patients recover within two days to one week after onset of illness. However, a small percentage (8-10%) of people infected with RVFV develops much more severe symptoms. There is a growing concern that RVFV will extend its current range due to the wide variety of mosquito species able to transmit to several mammal hosts.
Scientists at the University of Montpellier (Montpellier, France) and their colleagues developed a first-line lateral flow immunochromatographic strip test (LFT) for the detection of the nucleoprotein (N) of the RVF virus (RVFV). Its diagnostic performance characteristics were evaluated using reference stocks isolates recovered from different hosts and in geographic regions mimicking clinical specimens and from known RVF negative serum samples.
The test strip was constructed on the principles of immunochromatography using colloidal-gold-labeled monoclonal antibodies (Mabs). The team used the two Mabs generated against the N protein of RVFV: the Mab 8E10-4A4 gold conjugate and the Mab 10H3-4E4-3D5. Mab 10H3-4E4-3D5 was immobilized onto a nitrocellulose membrane for the test line zone and rabbit anti-mouse antibodies were immobilized for the control line zone to capture unbound Mab. The test (T) and control (C) lines were checked for the development of color after 10 minutes and again after 30 minutes as it might take longer time for weak positives to form a visual band scored subjectively from negative to strong.
A total of 25 isolated strains mimicking clinical specimens of different geographical origins and 10 clinical samples originating from an ongoing outbreak in 2019 detected RVF positive by a TaqMan RT-PCR technique which is considered as the current reference detection system were also detected positive by the LFT giving a diagnostic sensitivity of 100%. Diagnostic specificity (DSp) was assessed on 160 serum samples known to be negative for RVFV by sero-neutralization test and cELISA but collected in tropical countries where RVF has been circulating to detect possible cross reactions or in other areas where RVF introduction is considered at risk. The test gave a DSp of 98.81% and there was an absence of cross-reactivity with viruses belonging to different genera.
The authors concluded that the specificity and sensitivity of the evaluated test are lower than the ones of molecular-based techniques (LAMP, PCR) but are adequate for specific rapid initial detection of RVF outbreaks or disease surveillance in control programs. The fact no specialized reagents and laboratory equipment are needed, make this assay a valuable, first-line diagnostic tool in resource-poor diagnostic territories for on-site RVFV detection, however the staff require training. The study was published on September 11, 2019, in the journal PLOS NTD.
Related Links:
University of Montpellier
Latest Microbiology News
- FDA-Cleared Multiplex PCR Test Detects 13 Respiratory Pathogens in a Single Sample
- One-Hour Molecular Panel Expands Bloodstream Infection Testing for Gram-Negative Pathogens
- FDA Clears Rapid Phenotypic Antimicrobial Susceptibility System for Positive Blood Cultures
- New Urine Test Expands Mycotoxin Analysis to 31 Markers for Broader Exposure Assessment
- Collaboration Targets Blood-Based Ebola Detection Outside Central Laboratories
- Study Finds Frequent Overlap in Antibodies to Lyme and Other Tick-Borne Pathogens
- Early-Life Gut Microbiome Changes May Help Assess Type 1 Diabetes Risk
- FDA Breakthrough-Designated Urine Panel Aims to Shorten Pathogen and Susceptibility Testing
- Expanded Newborn Screening Program Increases Detection of Congenital Cytomegalovirus
- Genetic Studies Uncover Mechanisms Driving Drug Resistance in Superbugs
- Magnetic Nanoparticles Enable More Sensitive Beta-Lactam Allergy Testing
- Diagnostic Stewardship Guide Targets Testing Overuse and Hospital Cost Pressures
- Infant Skin Microbiome Show Links to Later Eczema and Food Allergies
- Research Strengthens Bundibugyo Virus Outbreak Readiness with Faster Diagnostics
- Gut Microbiome Classifier Improves Colorectal Cancer Risk Stratification
- New Diagnostic Workflow Identifies Bloodstream Pathogens and Antibiotic Response in Hours
Channels
Clinical Chemistry
view channel
Screening After Pneumococcal Disease May Reveal Undiagnosed Blood Cancer or Immune Disorders
Severe pneumococcal disease requiring hospitalization often presents as pneumonia, particularly in older adults and people with cancer or compromised immune function. Because M protein testing and antibody... Read more
Global Survey Underscores Need to Standardize Bone Biomarker Testing
Bone and mineral metabolism biomarkers can complement dual-energy X-ray absorptiometry (DXA) by providing information on disease activity and treatment response. For more than 20 years, standardization... Read more
Label-Free Platform Combines Microfluidics and AI for Circulating Tumor Cell Analysis
Liquid biopsy relies on detecting rare tumor-derived material in blood, but circulating tumor cells (CTCs) are especially difficult to capture because they are vastly outnumbered by normal blood cells.... Read more
Rapid D-Dimer Assay Supports Exclusion and Monitoring of Serious Clotting Conditions
Blood clots can rapidly become life‑threatening and affect approximately 10 million people worldwide each year. During time‑sensitive evaluations, clinicians use D‑dimer testing to help rule out deep vein... Read moreMolecular Diagnostics
view channel
Urine-Based RNA Improves Bladder Cancer Detection and Monitoring
Bladder cancer affects about 85,000 people in the United States each year and is prone to recurrence. Diagnosis and surveillance commonly rely on cystoscopy, an endoscopic examination that can miss up... Read more
Blood RNA Panel Predicts Lung Cancer Risk Years Before Diagnosis
Lung cancer may begin developing during a preclinical period when the disease remains clinically undetected, creating a challenge for identifying individuals at elevated risk years before diagnosis.... Read moreHematology
view channel
New Donor Genetic Marker May Help Predict Stem Cell Transplant Success
Donor selection for hematopoietic stem cell transplantation plays a major role in relapse risk and survival for patients with blood cancers and other blood disorders. Despite advances in genotyping, uncertainty... Read more
Updated Ferritin Thresholds Improve Detection of Iron Deficiency
Iron deficiency is one of the most common health conditions worldwide, yet its nonspecific symptoms can delay diagnosis for months. Variation in testing practices and ferritin thresholds may contribute... Read moreImmunology
view channel
Blood Test Differentiates Bacterial and Viral Infections in Febrile Infants
Fever in infants younger than 3 months is treated as a medical emergency because infections can become life-threatening while the immune system is still developing. Emergency department teams must quickly... Read more
New Autoantibody Test Targets Pre-Symptomatic Type 1 Diabetes Screening
Type 1 diabetes is often first recognized only after substantial beta-cell destruction, sometimes presenting as diabetic ketoacidosis. Population-scale screening could identify children at elevated risk... Read morePathology
view channel
Genomic Classifier Predicts Benefit From Adding Hormone Therapy to Salvage Prostate Radiation
Men who have undergone prostatectomy for prostate cancer may later develop a detectable or rising prostate-specific antigen, prompting salvage radiation therapy. A key challenge is determining who is most... Read more
New AI Model Maps Where Glioblastoma Could Return After Surgery
Glioblastoma is the most common malignant brain tumor in adults and the most lethal, with median survival of about 17 months after diagnosis. Even after surgeons remove all visible tumor and patients receive... Read moreTechnology
view channelLaser-Based Swab Analysis Shows Promise for Detecting Disease-Linked Odor Patterns
Disease-related changes in volatile organic compounds can alter body odor, producing measurable patterns in exhaled breath and bodily fluids. Current analytical methods can be complex, time-consuming,... Read more
Laser-Enhanced Assay Boosts Sensitivity for Colorectal Cancer Biomarker Detection
Colorectal cancer is the third most commonly diagnosed cancer and the second leading cause of cancer-related death worldwide. Early detection remains critical, but cancer biomarkers can produce only faint... Read moreIndustry
view channel
Collaboration Combines AI Cognitive Assessment and RNA Blood Testing for Earlier Alzheimer’s Detection
Alzheimer’s disease is often identified only after substantial neurodegeneration, partly because current diagnostic pathways are fragmented and difficult to scale. As treatment shifts toward earlier intervention,... Read more
Mayo Clinic Laboratories and Pathology Asia Expand Genomic Testing Across Asia-Pacific
Mayo Clinic Laboratories and Pathology Asia Holdings (PAH), together with subsidiary LifeStrands Genomics, announced a strategic investment and collaboration focused on expanding access to advanced diagnostics... Read more







